Compass Therapeutics (NASDAQ:CMPX - Get Free Report)'s stock had its "buy" rating reissued by investment analysts at HC Wainwright in a research note issued on Tuesday, Benzinga reports. They currently have a $10.00 target price on the stock.
Separately, Wedbush reissued an "outperform" rating and set a $8.00 target price on shares of Compass Therapeutics in a research note on Friday, March 22nd.
View Our Latest Report on CMPX
Compass Therapeutics Price Performance
Compass Therapeutics stock traded up $0.05 during trading on Tuesday, reaching $1.62. 371,570 shares of the company were exchanged, compared to its average volume of 441,217. Compass Therapeutics has a 52-week low of $1.15 and a 52-week high of $3.62. The stock's 50 day simple moving average is $1.77 and its two-hundred day simple moving average is $1.68. The company has a market capitalization of $222.21 million, a P/E ratio of -4.75 and a beta of 0.92.
Compass Therapeutics (NASDAQ:CMPX - Get Free Report) last released its quarterly earnings results on Thursday, March 21st. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02). As a group, equities analysts forecast that Compass Therapeutics will post -0.48 earnings per share for the current year.
Hedge Funds Weigh In On Compass Therapeutics
Large investors have recently made changes to their positions in the stock. SG Americas Securities LLC increased its position in Compass Therapeutics by 22.7% during the fourth quarter. SG Americas Securities LLC now owns 47,624 shares of the company's stock worth $74,000 after buying an additional 8,817 shares in the last quarter. Simplicity Wealth LLC acquired a new stake in shares of Compass Therapeutics during the 1st quarter worth about $80,000. Bleakley Financial Group LLC purchased a new stake in shares of Compass Therapeutics during the first quarter worth about $80,000. Pale Fire Capital SE purchased a new position in shares of Compass Therapeutics during the third quarter valued at approximately $89,000. Finally, B. Riley Wealth Advisors Inc. boosted its position in Compass Therapeutics by 235.2% during the third quarter. B. Riley Wealth Advisors Inc. now owns 50,000 shares of the company's stock worth $98,000 after acquiring an additional 35,082 shares during the last quarter. Hedge funds and other institutional investors own 68.43% of the company's stock.
Compass Therapeutics Company Profile
(
Get Free Report)
Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.
See Also
Before you consider Compass Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Therapeutics wasn't on the list.
While Compass Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
